

Work Plan

Nanomedicines Working Group

Date: 18 October 2023

Chair: Wenlei Jiang, FDA, United States

Co-Chair: Nadia Soledad Villar, ANMAT, Argentina

Chair Supporter: Debbie Cordaro, FDA, United States

1. KEY MILESTONES AND DELIVERABLES

1.1. Current status of key milestones and deliverables

Past completion date	Objective	Key Milestone or Deliverable
2016	<i>Information Sharing & Mapping</i>	<i>IPRP NMWG Liposome Survey results published on the NMWG landing page of the IPRP website</i>
January 2018	<i>Information Sharing & Mapping</i>	<i>JRC Technical report: Mapping Nanomedicine Terminology in the Regulatory Landscape published on the NMWG landing page of the IPRP website</i>
Apr 2020	<i>Information Sharing & Mapping</i>	<i>Liposome survey published on the NMWG landing page of IPRP website</i>
Jun 2021	<i>Information Sharing & Mapping</i>	<i>Liposome survey analysis completed and updated to the NMWG</i>
Sep-Dec 2021	<i>Information Sharing & Mapping</i>	<i>Zoom Nano proposal announced; inaugural presentation delivered Dec 2021</i>
Nov 2021 - Nov 2022	<i>Identification of NWG agency expertise and needs</i>	<i>Chat One-on-One with 10 regulatory agencies Chair and Co-chair conduct a 30-min phone call with individual agency representatives</i>
May 2022	<i>Information Sharing & Mapping</i>	<i>Members presented at virtual regulatory session at CLINAM May 2022 meeting</i>
Oct 2022	<i>Information Sharing & Mapping</i>	<i>Members presented at in-person Global Summit Regulatory Science (GSRS) Oct 2022 meeting</i>
Jan - Nov 2022	<i>Information Sharing & Mapping</i>	<i>Six Zoom Nano presentations delivered</i>

Jan – Nov 2023	<i>Information Sharing & Mapping</i>	<i>Three Zoom Nano presentations delivered</i>
Jan – Mar 2023	<i>Support liposome standards development and dissemination</i>	<i>Three most recent liposome standards shared among the group</i>
Jan – Nov 2023	<i>Information Sharing & Mapping</i>	<i>Archived guidelines published by NWG member agencies and other regional updates on sharepoint site</i>
Oct 2023	<i>Information Sharing & Mapping</i>	<i>Held face-to-face meeting, discussed regulatory issues and research of lipid nanoparticles and product-specific guidances</i>
Jan - Nov 2023	<i>Identification of NWG agency expertise and needs</i>	<i>Chat One-on-One with 3 regulatory agencies Chair and Co-chair conducted a 30-min phone call with individual agency representatives</i>

1.2. Future anticipated key milestones

Expected future completion date	Objective	Key Milestone or Deliverable
Dec 2023 or Early 2024	<i>Information Sharing & Mapping - Liposomes</i>	<i>Publish Liposome Survey on a peer-reviewed journal</i>
2024 - quarterly	<i>Information sharing/training</i>	<i>Hold quarterly teleconference</i>
2024 - quarterly	<i>Information sharing/training</i>	<i>Zoom Nano - Regulatory Considerations for lipid nanoparticle platform technologies used to deliver mRNA/DNA vaccines, gene therapies and siRNA</i>
Jan – Oct 2024	<i>Evaluate and plan 2024 face-to-face meeting</i>	<i>Evaluate the feasibility of holding a face-to-face meeting If feasible, plan and organize face-to-face meeting</i>

2. TIMELINE FOR SPECIFIC TASKS

Beginning date	End date	Task / Activity	Details
<i>Dec 2023</i>	<i>Dec 2024</i>	<i>Teleconferences</i>	<i>Hold quarterly meeting to discuss emerging topics related to nanomedicine development and regulation</i>
<i>Dec 2023</i>	<i>Dec 2024</i>	<i>Zoom Nano - Information sharing and mapping, regulatory updates, training</i>	<i>Hold at least 3 webinars. Continue on Theme 2: lipid nanoparticle platform technologies used to deliver RNA/DNA vaccines, gene therapies and siRNA</i>

Dec 2023	Dec 2024	<i>Product-specific guidance Subgroup</i>	<ul style="list-style-type: none"> - <i>Continue collecting survey information from different agencies</i> - <i>Further evaluate the feasibility of developing a harmonized product-specific guidance</i> - <i>Prepare a document template to summarize consensus considerations for PSG</i>
Dec 2023	Dec 2024	<i>Lipid Nanoparticle Subgroup</i>	<ul style="list-style-type: none"> - <i>Continue collecting survey information from different agencies</i> - <i>Reach consensus on biological and chemical product classification of mRNA and lipid nanoparticles</i> - <i>Clarify considerations on API and excipients</i> - <i>Discuss analytical techniques for the characterization</i> - <i>Understand recommended studies for post approval changes</i>
Sep 2024	Dec 2024	<i>Develop 2024 Work Plan</i>	